Immunotherapy in patients with local HPV infection and high-grade squamous intraepithelial lesion following uterine cervical conization was written by Kovachev, Stefan Miladinov. And the article was included in Immunopharmacology and Immunotoxicology in 2020.Safety of 4-Acetamidobenzoic acid,9-((2R,3R,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3H-purin-6(9H)-one,1-(Dimethylamino)propan-2-ol (3:1:3) This article mentions the following:
To establish the clearance of cervical human papillomavirus (HPV) infection following postoperative immunotherapy with inosine pranobex in women receiving surgical treatment of established high-grade squamous intraepithelial lesion (HSIL) of the uterine cervix. Over the six-year study period, 32 women with cervical HPV infection following electroconization (loop electrosurgical excision procedure) of the uterine cervix for established HSIL were randomly divided into two groups: I (n = 10) without and II (n = 22) with postoperative inosine pranobex immunotherapy. Follow-up after 24 and 48 mo included cervical testing for HPV persistence and after 12, 24, and 48 mo with cytol. and colposcopy for dysplasia relapse (confirmed histol.). Relapse monitoring in 32 women after 12 mo revealed 1 and 0 HSIL pos. in groups I and II, resp.; after 24 mo an addnl. 3 patients in each group were pos.; and after 48 mo an addnl. 3 and 1 patients were pos. in groups I and II, resp. (p < .05). The groups significantly differed (p < .05) with regard to clearing the most common high-risk HPV genotypes (HPV 16 and HPV 56). Inosine pranobex immunotherapy in HPV-pos. patients following cervical conization significantly increased the clearance of viral infection with high-risk genotypes and reduced relapse of HSIL. In the experiment, the researchers used many compounds, for example, 4-Acetamidobenzoic acid,9-((2R,3R,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3H-purin-6(9H)-one,1-(Dimethylamino)propan-2-ol (3:1:3) (cas: 36703-88-5Safety of 4-Acetamidobenzoic acid,9-((2R,3R,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3H-purin-6(9H)-one,1-(Dimethylamino)propan-2-ol (3:1:3)).
4-Acetamidobenzoic acid,9-((2R,3R,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3H-purin-6(9H)-one,1-(Dimethylamino)propan-2-ol (3:1:3) (cas: 36703-88-5) belongs to tetrahydrofuran derivatives. Tetrahydrofuran (THF), or oxolane, is mainly used as a precursor to polymers. Being polar and having a wide liquid range, THF is a versatile solvent. Oxidations have also proved to be valuable and efficient approaches to chiral tetrahydrofuran derivatives.Safety of 4-Acetamidobenzoic acid,9-((2R,3R,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3H-purin-6(9H)-one,1-(Dimethylamino)propan-2-ol (3:1:3)
Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem